raloxifene hydrochloride has been researched along with angiotensin ii in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JW; Cui, YH; Pan, H; Wang, TH; Xiang, QL | 1 |
| Azizian, H; Bashiri, H; Ebrahimi, MN; Khaksari, M; Raji-Amirhasani, A | 1 |
2 other study(ies) available for raloxifene hydrochloride and angiotensin ii
| Article | Year |
|---|---|
Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade.
Topics: Angiotensin II; Animals; Blotting, Western; Breast; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Endothelial Cells; Estradiol; Estrogen Receptor beta; Female; Fluorescent Antibody Technique; Humans; Janus Kinases; Muscle, Smooth, Vascular; Phosphorylation; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2007 |
Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II.
Topics: Angiotensin II; Animals; Cytokines; Diabetes Mellitus, Type 2; Estrogens; Female; Interleukin-10; Postmenopause; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Necrosis Factor-alpha | 2022 |